


**BOEHRINGER
INGELHEIM**

**A LEADER IN
STROKE
PREVENTION &
TREATMENT**

R&D OVERVIEW – SIX THERAPEUTIC AREAS

| Research Areas | Therapeutic Focus |
|-----------------|--|
| Cardiometabolic | Cardiovascular outcome event prevention (stroke, heart attack, death) Diabetes, Metabolic Syndrome, Thromboembolic events |
| Oncology | Lymphomas, Leukaemias, Solid tumours |
| Respiratory | Asthma, COPD, Idiopathic Pulmonary Fibrosis |
| Neurology | Alzheimer's Disease, Chronic Pain, Migraine, Parkinson's Disease |
| Immunology | Multiple Sclerosis, Psoriasis, Rheumatoid Arthritis |
| Virology | Hepatitis C, HIV/AIDS |

LONG TERM COMMITMENT TO THE TREATMENT & PREVENTION OF STROKE



ACTILYSE® - EUROPEAN COOPERATIVE ACUTE STROKE STUDY 3 (ECASS 3)

- ECASS 3 tested the efficacy and safety of ACTILYSE® administered between 3 and 4.5 hours after onset of a stroke
- ECASS 3 showed ACTILYSE®:
 - Improved 1^o efficacy outcome at 90 days (more patients had modified Rankin scores 0-1; Odds Ratio 1.34)
 - Improved 2^o efficacy outcome at 90 days (composite of several stroke scales measuring the ability to return to an independent lifestyle; Odds Ratio 1.28)
 - Safety profile in ECASS 3 consistent to treatment in 0-3 hour time window



Early treatment with ACTILYSE® offers patients with acute ischaemic stroke the greatest chance of recovery

MICARDIS® - The ONTARGET Study

- ONTARGET is the largest ARB outcome study ever undertaken
 - Compared MICARDIS® to gold standard ACE-I ramipril for CV protection
 - Included a broad cross section of patients at high-risk for CV events
- ONTARGET demonstrated:
 - MICARDIS® effective in preventing CV death, MI and stroke
 - MICARDIS® better tolerated with better medication adherence

 **MICARDIS® is the only ARB with an indication for CV protection in a broad group of patients at high-risk for CV events**

THE RE-VOLUTION[®] TRIAL PROGRAMME

- Evaluating the efficacy and safety of dabigatran etexilate against current standard therapy in nearly 40,000 patients

ARTERIAL DISORDERS

- Stroke Prevention in AF



- Secondary prevention of Cardiac Events in Patients with ACS*



* PHASE II TRIAL

 ONGOING

 COMPLETED

VENOUS DISORDERS

- Primary VTE Prevention



- Acute VTE Treatment



- Secondary VTE Prevention

